Intelligent Bio Solutions Inc. announced its financial results for the fiscal fourth quarter and full year ended June 30, 2025.
The company achieved sequential and year-on-year revenue growth of 16%, driven by increased demand for drug testing cartridges.
Progress was made towards securing FDA 510(k) clearance for expanding into the U.S. market beyond current settings.
Revenue Growth
16% revenue growth in the fiscal fourth quarter, supported by increased demand for drug testing cartridges.
FDA Clearance Progress
Focused on securing FDA 510(k) clearance for opiate test system for codeine in the U.S. setting the path for market expansion.
Market Expansion
Expanding commercial presence internationally with over 450 accounts in 24 countries and 18 distribution partners.
- The revenue from sales of goods in fiscal Q4 increased by 16% year-on-year and quarter-on-quarter, driven by cartridge sales.
- Revenue from cartridge sales grew by 9% quarter-on-quarter and 24% year-on-year for the fiscal fourth quarter.
- Expansion efforts beyond the U.S. are underway, with scoping in Canada, Indonesia, and the Philippines.
Intelligent Bio Solutions continues to focus on accelerating growth, advancing operational excellence, and expanding into the U.S. market. The company's strategic priorities for fiscal 2026 are set to drive further success.